U.S. gene study raises hope for Merck cholesterol drug Zetia

November 12, 2014 10:02 PM

11 0

CHICAGO (Reuters) - Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia.

The study involved individuals with mutations in a gene called NPC1L1, the gene targeted by Zetia, a cholesterol fighter known generically as ezetimibe.

Also read: Here's your chance to live on a private island and work for Richard Branson

Read more

To category page